citalopram has been researched along with Autism in 14 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy and safety of citalopram hydrobromide therapy for repetitive behavior in children with autism spectrum disorders." | 9.14 | Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. ( Anagnostou, E; Bregman, JD; Donnelly, CL; Dukes, K; Hirtz, D; Hollander, E; King, BH; McCracken, JT; Ritz, L; Scahill, L; Sikich, L; Sullivan, L; Wagner, A, 2009) |
| "To determine the efficacy and safety of citalopram hydrobromide therapy for repetitive behavior in children with autism spectrum disorders." | 5.14 | Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. ( Anagnostou, E; Bregman, JD; Donnelly, CL; Dukes, K; Hirtz, D; Hollander, E; King, BH; McCracken, JT; Ritz, L; Scahill, L; Sikich, L; Sullivan, L; Wagner, A, 2009) |
| " Search terms included autism, autistic disorder, citalopram, fluoxetine, fluvoxamine, paroxetine, selective serotonin-reuptake inhibitors, and sertraline." | 4.82 | Treating functional impairment of autism with selective serotonin-reuptake inhibitors. ( Eichner, SF; Jones, JR; Moore, ML, 2004) |
| "improves the core features of autism (social interaction, communication and behavioural problems);2." | 2.49 | Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). ( Brignell, A; Hazell, P; Randall, M; Silove, N; Williams, K, 2013) |
| "improves the core features of autism (social interaction, communication and behavioural problems); 2." | 2.46 | Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). ( Hazell, P; Silove, N; Wheeler, DM; Williams, K, 2010) |
| "We propose that catatonia should be ruled out as a cause of regression sometimes seen in adolescents with autism, and that catatonia of autism may index a distinct subtype with a particularly poor outcome." | 2.43 | Catatonia in autism: a distinct subtype? ( Ghaziuddin, M; Ghaziuddin, N; Quinlan, P, 2005) |
| "Autism is characterized by abnormal prefrontal brain activation during cognitive control, a potential biomarker of repetitive behaviors." | 1.36 | fMRI tracks reductions in repetitive behaviors in autism: two case studies. ( Bodfish, J; Dichter, GS; Felder, JN; Lam, KS; Mahorney, S; Sikich, L; Turner-Brown, L, 2010) |
| "Citalopram was the most preferred antidepressant and Carbamazepine, the most preferred mood stabilizer/antiepileptic." | 1.35 | Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey. ( Deb, S; Unwin, GL, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JY | 1 |
| Fusar-Poli, P | 1 |
| Shin, JI | 1 |
| Williams, K | 2 |
| Brignell, A | 1 |
| Randall, M | 1 |
| Silove, N | 2 |
| Hazell, P | 2 |
| Schmidt, C | 1 |
| Volkmar, FR | 1 |
| King, BH | 1 |
| Hollander, E | 1 |
| Sikich, L | 2 |
| McCracken, JT | 1 |
| Scahill, L | 1 |
| Bregman, JD | 1 |
| Donnelly, CL | 1 |
| Anagnostou, E | 1 |
| Dukes, K | 1 |
| Sullivan, L | 1 |
| Hirtz, D | 1 |
| Wagner, A | 1 |
| Ritz, L | 1 |
| Dichter, GS | 1 |
| Mahorney, S | 1 |
| Felder, JN | 1 |
| Lam, KS | 1 |
| Turner-Brown, L | 1 |
| Bodfish, J | 1 |
| Wheeler, DM | 1 |
| Anderson, GM | 1 |
| Gutknecht, L | 1 |
| Cohen, DJ | 1 |
| Brailly-Tabard, S | 1 |
| Cohen, JH | 1 |
| Ferrari, P | 1 |
| Roubertoux, PL | 1 |
| Tordjman, S | 1 |
| Namerow, L | 1 |
| Thomas, P | 1 |
| Bostic, JQ | 1 |
| Prince, J | 1 |
| Monuteaux, MC | 1 |
| Moore, ML | 1 |
| Eichner, SF | 1 |
| Jones, JR | 1 |
| Ghaziuddin, M | 1 |
| Quinlan, P | 1 |
| Ghaziuddin, N | 1 |
| Owley, T | 1 |
| Walton, L | 1 |
| Salt, J | 1 |
| Guter, SJ | 1 |
| Winnega, M | 1 |
| Leventhal, BL | 1 |
| Cook, EH | 1 |
| Unwin, GL | 1 |
| Deb, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior[NCT00086645] | Phase 2 | 149 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)[NCT02410902] | Phase 3 | 190 participants (Actual) | Interventional | 2015-05-13 | Completed | ||
| An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin[NCT02649959] | Phase 3 | 405 participants (Anticipated) | Interventional | 2015-10-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist (ABC) - Community sub scale for Irritability/Agitation (ABC-I) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-I is one of five discrete sub scales measured by the ABC. The scale range is 0-45. A higher score reflects higher severity of symptoms (irritability). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. The score was automatically calculated by the EDC. (NCT02410902)
Timeframe: Screening through Week 12/Termination
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -8.0 |
| Placebo | -5.5 |
Secondary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist- Community (ABC) sub scale for Lethargy / Social Withdrawal (ABC-L) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-L is one of five discrete sub scales measured by the ABC. The scale range is 0-48. A higher score reflects higher severity of symptoms (lethargy). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. (NCT02410902)
Timeframe: Screening through Week 12/Termination.
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -7.9 |
| Placebo | -6.6 |
4 reviews available for citalopram and Autism
| Article | Year |
|---|---|
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Child Development Disorders, Pervasive; Citalopram; Fe | 2013 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
Topics: Autistic Disorder; Citalopram; Clinical Trials as Topic; Fluoxetine; Fluvoxamine; Humans; Paroxetine | 2004 |
Catatonia in autism: a distinct subtype?
Topics: Adolescent; Antidepressive Agents, Second-Generation; Autistic Disorder; Catatonia; Citalopram; Comb | 2005 |
2 trials available for citalopram and Autism
| Article | Year |
|---|---|
Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.
Topics: Adolescent; Asperger Syndrome; Attention; Autistic Disorder; Child; Child Development Disorders, Per | 2009 |
An open-label trial of escitalopram in pervasive developmental disorders.
Topics: Adolescent; Autistic Disorder; Child; Child Development Disorders, Pervasive; Citalopram; Dose-Respo | 2005 |
8 other studies available for citalopram and Autism
| Article | Year |
|---|---|
SSRIs and autism: interpreting an umbrella review - Authors' reply.
Topics: Autistic Disorder; Citalopram; Humans; Selective Serotonin Reuptake Inhibitors | 2019 |
Mental health: thinking from the gut.
Topics: Animals; Anxiety; Autistic Disorder; Bacteroides fragilis; Bifidobacterium; Blood-Brain Barrier; Bra | 2015 |
Citalopram treatment in children with autism spectrum disorders and high levels of repetitive behavior.
Topics: Adolescent; Autistic Disorder; Child; Child, Preschool; Citalopram; Double-Blind Method; Humans; Imp | 2009 |
Drug fails to subdue repetitive behavior in children with autism spectrum disorders.
Topics: Adolescent; Autistic Disorder; Child; Child, Preschool; Citalopram; Humans; Randomized Controlled Tr | 2009 |
fMRI tracks reductions in repetitive behaviors in autism: two case studies.
Topics: Autistic Disorder; Behavior; Citalopram; Humans; Magnetic Resonance Imaging; Male; Neuropsychologica | 2010 |
Serotonin transporter promoter variants in autism: functional effects and relationship to platelet hyperserotonemia.
Topics: Adolescent; Autistic Disorder; Blood Platelets; Carrier Proteins; Child; Citalopram; Female; Genetic | 2002 |
Use of citalopram in pervasive developmental disorders.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Asperger Syndrome; Autistic Disorder; Child; C | 2003 |
Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey.
Topics: Adult; Aggression; Antipsychotic Agents; Attitude of Health Personnel; Autistic Disorder; Carbamazep | 2008 |